Hemispherx Biopharma (HEB) Announces Positive Retrospective Analysis of Ampligen Phase 3 in CFS/ME

October 31, 2016 8:35 AM

Hemispherx Biopharma (NYSE: HEB) announced that a retrospective analysis of the AMP-516 Phase III trial of Ampligen® in patients with ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found